Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, El Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C Snijders, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W, Harakalova, M, Afd Pharmacoepi & Clinical Pharmacology, Interne geneeskunde GD, dCSCA AVR, Sub Inorganic Chemistry and Catalysis, LS Vertaalwetenschap, CS_Genetics
Publikováno v:
Clinical Epigenetics, 13(1):61. BioMed Central Ltd.
Clinical epigenetics, 13(1):61. Springer Verlag
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, el Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C S, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W & Harakalova, M 2021, ' Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations ', Clinical epigenetics, vol. 13, no. 1, 61 . https://doi.org/10.1186/s13148-021-01043-3
Clinical Epigenetics
Clinical Epigenetics, 13(1), 1. BioMed Central
Clinical Epigenetics, 13(1). BMC
Clinical epigenetics, 13(1):61. Springer Verlag
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, el Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C S, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W & Harakalova, M 2021, ' Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations ', Clinical epigenetics, vol. 13, no. 1, 61 . https://doi.org/10.1186/s13148-021-01043-3
Clinical Epigenetics
Clinical Epigenetics, 13(1), 1. BioMed Central
Clinical Epigenetics, 13(1). BMC
Background Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the cardiac muscle, frequently caused by mutations in MYBPC3. However, little is known about the upstream pathways and key regulators causing the disease. Therefore, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48513be4255f80671f2b51e974fc2314
https://pure.eur.nl/en/publications/a2126346-ea8a-4e36-ba69-e93fb8de9a58
https://pure.eur.nl/en/publications/a2126346-ea8a-4e36-ba69-e93fb8de9a58
Autor:
de Gooijer, Mark C, de Vries, Nienke A, Buckle, Tessa, Buil, Levi C M, Beijnen, Jos H, Boogerd, Willem, van Tellingen, Olaf, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 710-720 (2018)
Neoplasia, 20(7), 710. Elsevier
Neoplasia (New York, N.Y.)
Neoplasia, 20(7), 710. Elsevier
Neoplasia (New York, N.Y.)
The anticancer drug temozolomide is the only drug with proven activity against high-grade gliomas and has therefore become a part of the standard treatment of these tumors. P-glycoprotein (P-gp; ABCB1) and breast cancer resistance protein (BCRP; ABCG
Autor:
Mahmoudpour, Seyed H., Veluchamy, Abirami, Siddiqui, Moneeza K., Asselbergs, Folkert W., Souverein, Patrick C., De Keyser, Catherine E., Hofman, Albert, Lang, Chim C., Doney, Alexander S.F., Stricker, Bruno H., De Boer, Anthonius, Maitland-Van Der Zee, Anke H., Palmer, Colin N.A., Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Pharmacogenetics Genomics, 27(3), 112-119. Lippincott Williams & Wilkins
Pharmacogenetics and Genomics, 27(3), 112. Lippincott Williams and Wilkins
Pharmacogenetics and genomics, 27(3), 112-119. Lippincott Williams and Wilkins
Pharmacogenetics and genomics, 27(3), 112. Lippincott Williams and Wilkins
Pharmacogenetics and Genomics, 27(3), 112. Lippincott Williams and Wilkins
Pharmacogenetics and genomics, 27(3), 112-119. Lippincott Williams and Wilkins
Pharmacogenetics and genomics, 27(3), 112. Lippincott Williams and Wilkins
Objectives To identify single nucleotide polymorphisms (SNPs) associated with switching from an angiotensin-converting enzyme (ACE)-inhibitor to an angiotensin receptor blocker. Methods Two cohorts of patients starting ACE-inhibitors were identified
Autor:
Broekman, Mark M.T.J., Coenen, Marieke J H, van Marrewijk, Corine J, Wanten, Geert J A, Wong, Dennis R, Verbeek, Andre L.M., Klungel, Olaf H., Hooymans, Piet M, Guchelaar, Henk-Jan, Scheffer, Hans, Derijks, Luc J J, De Jong, Dirk J., Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Inflammatory Bowel Diseases, 23, 10, pp. 1873-1881
Inflammatory Bowel Diseases, 23(10), 1873. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 23(10), 1873-1881
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 23, 1873-1881
Inflammatory Bowel Diseases, 23(10), 1873. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 23(10), 1873-1881
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 23, 1873-1881
Article first published online 20 june 2017. Supplemental Digital Content is Available in the Text.
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as first-choice
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as first-choice
Autor:
van Hoppe, Stéphanie, Jamalpoor, Amer, Rood, Johannes J M, Wagenaar, Els, Sparidans, Rolf W, Beijnen, Jos H, Schinkel, Alfred H, Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmacological Research, 146. Academic Press Inc.
Osimertinib is an irreversible EGFR inhibitor registered for advanced NSCLC patients whose tumors harbor recurrent somatic activating mutations in EGFR (EGFRm+) or the frequently occurring EGFR-T790M resistance mutation. Using in vitro transport assa
Autor:
Li, Wenlong, Sparidans, Rolf W., Wang, Yaogeng, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H., Afd Pharmacoepi & Clinical Pharmacology, Afd Chemical Biology and Drug Discovery, Pharmacoepidemiology and Clinical Pharmacology, Chemical Biology and Drug Discovery
Publikováno v:
Pharmacological Research, 137, 47. Academic Press Inc.
Brigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC). Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60fd875538f0101a346c51b59df46cc0
https://dspace.library.uu.nl/handle/1874/374357
https://dspace.library.uu.nl/handle/1874/374357
Autor:
Li, Wenlong, Sparidans, Rolf W, Wang, Yaogeng, Lebre, Maria C, Wagenaar, Els, Beijnen, Jos H, Schinkel, Alfred H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
International Journal of Cancer, 143(8), 2029. Wiley-Liss Inc.
Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. With therapy-resistant brain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43adde3558244fd803479b5c45f2004
https://dspace.library.uu.nl/handle/1874/371773
https://dspace.library.uu.nl/handle/1874/371773
Autor:
de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., Herder, Gerarda J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Thoracic Cancer, 11(7), 1790. Blackwell Publishing Asia Pty Ltd
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 7, Pp 1790-1800 (2020)
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 7, Pp 1790-1800 (2020)
Background In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision-making. The objective of this study was to investigate carcinoembryonic antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4509620a259b07436012699b43bbe48a
https://dspace.library.uu.nl/handle/1874/408616
https://dspace.library.uu.nl/handle/1874/408616
Autor:
de Gooijer, Mark C, Buil, Levi C M, Çitirikkaya, Ceren H, Hermans, Jill, Beijnen, Jos H, van Tellingen, Olaf, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Molecular Pharmaceutics, 15(11), 5236. American Chemical Society
Poly (ADP-ribose) polymerase (PARP) inhibitors are a relatively new class of anticancer agents that have attracted attention for treatment of glioblastoma because of their ability to potentiate temozolomide chemotherapy. Previous studies have demonst
Autor:
Van Hoppe, Stéphanie, Rood, Johannes J.M., Buil, Levi, Wagenaar, Els, Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Molecular Pharmaceutics, 15(11), 5124. American Chemical Society
Ibrutinib (Imbruvica), an oral tyrosine kinase inhibitor (TKI) approved for treatment of B-cell malignancies, irreversibly inhibits the Bruton's tyrosine kinase (BTK). Its abundant metabolite, dihydrodiol-ibrutinib (ibrutinib-DiOH), which is primaril